Efficacy and Safety of Different Doses of Bevacizumab Combined With Pemetrexed and Platinum in First-Line Treatment of Advanced NSCLC: A Retrospective-Real World Study

Chun-Hua Zhou†, Feng Yang‡, Wen-Juan Jiang†, Yong-Chang Zhang†, Hai-Yan Yang†, Liang Zeng†, Li Liu†, Yi Xiong†, Fan-Xu Zeng†, Zhan Wang‡ and Nong Yang‡

1Lung Cancer and Gastrointestinal Unit, Department of Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, 2Center of New Drug Clinical Trial, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China

Background: Bevacizumab was demonstrated to have efficacy in patients with NSCLC. However, application of different doses of bevacizumab in different clinical trials was overlooked. This study aims to investigate the effects and safety of different doses of bevacizumab in the treatment.

Methods: From January 2016 to March 2020, 79 patients with NSCLC received first-line combination treatment with chemotherapy (pemetrexed + platinum) and bevacizumab for four cycles; patients without progression after four cycles were randomly assigned to maintenance therapy with bevacizumab combined with pemetrexed, of which 57 patients received bevacizumab at a dose of 7.5 mg/kg and 22 patients at a dose of 15 mg/kg. The primary endpoint was progression-free survival, and secondary endpoints were overall response rate, disease control rate, and adverse events.

Results: There was no significant difference between two groups in effectiveness; Median PFS in 7.5 mg/kg group and in 15 mg/kg group were 8.0 and 8.7 months, respectively ($p = 0.663$), reaching the primary endpoint. The ORR and DCR in the bevacizumab 7.5 and 15 mg/kg group were 45.46 and 86.0% vs. 50 and 90.9% showing no statistical significance ($p = 0.804$ and $0.717$). Most of side effects were tolerable. The incidences of overall toxicities were higher in 15 mg/kg group ($p = 0.001$). No new safety signals were observed.

Conclusion: We did not detect significant difference of efficacy and safety between 7.5 mg/kg group and 15 mg/kg group for bevacizumab administration, the cost-effectiveness of the 7.5 mg/kg group was significantly better than that of the 15 mg/kg group.

Keywords: bevacizumab, chemotherapy, different dose, efficacy and safety, NSCLC
INTRODUCTION

Lung cancer is the most common cancer with leading cause of cancer deaths in China and worldwide (Chen et al., 2016; Siegel et al., 2018, 2019). In recent years, with the emerging of the tyrosine kinase inhibitors (TKIs) for patients with EGFR mutation, ALK rearrangement or ROS1 rearrangement, and immune checkpoint inhibitors, the treatment for advanced NSCLC has changed greatly and the 5-years survival rate of patients has also been greatly improved. However, the use of targeted therapy may be restricted to patients whose tumor has a specific gene mutation and the application of immune monotherapy requires specific immune markers, and the ORR is limited (Reck et al., 2019). In recent years, with the effectiveness of anti-angiogenesis therapy, the prognosis of patients with NSCLC has been greatly improved. Bevacizumab is a humanized immunoglobulin G monoclonal antibody blocking VEGF-mediated signaling pathways and thus angiogenesis, so as to play an effective role of anti-tumor (Hanna et al., 2020).

Several clinical trials have confirmed that the combination of bevacizumab and chemotherapy (BC) significantly prolonged progression free survival (PFS) and overall survival (OS) in NSCLC patients as compared with chemo-monotherapy (Crino et al., 2010; Zhou et al., 2015; Rocco et al., 2019). BC has become the standard first-line clinical treatment for non-squamous NSCLC without driver gene mutations. However, the dose of bevacizumab was inconsistent in different studies. In ECOG4599, BEYOND and Pronounce, the dose of bevacizumab was used by 15 mg/kg, while 7.5 mg/kg was used in MO22089, and they were both with good overall efficacy and safety (Barlesi et al., 2013; Zhou et al., 2015; Zinner et al., 2015; Li et al., 2019).

There are few comparative studies of bevacizumab in NSCLC. Most treatment guidelines did not make a recommendation of the optimal dose to physicians. In AVAIL, bevacizumab was used by 7.5 or 15 mg/kg in BC regimen. The treatment efficacy of both bevacizumab groups seemed to be similar when compared to the placebo group. However, further analysis of 105 Asian patients in the study showed that there was OS benefit in the low-dose bevacizumab group, but not in the high-dose bevacizumab group. In terms of safety, the incidence of grade 3 or above adverse reactions in high-dose bevacizumab group was 44%, which was higher than that in low-dose bevacizumab group (33%) and chemotherapy group (33%) (Reck et al., 2009). Therefore, for Asian patients, low-dose bevacizumab combination therapy may be able to obtain better efficacy.

In this study, all patients received first-line bevacizumab plus pemetrexed-platinum (PC). In the JMDB study, PC was the preferred chemotherapy regimen for non-small cell lung cancer (Scagliotti et al., 2008). Moreover, many studies demonstrated that the combination of bevacizumab with PC was well tolerated in the treatment of NSCLC (Barlesi et al., 2013; Patel et al., 2013; Zinner et al., 2015; Xu et al., 2016; Shan et al., 2018; Tsutani et al., 2018; Kreis et al., 2019). We conducted the assessment of treatment with real world study to compare the efficacy and safety of low (7.5 mg/kg) and high (15 mg/kg) dose of bevacizumab in combination with PC in advanced non-squamous NSCLC.

PATIENTS AND METHODS

Patients

A total of 1,205 treatment-naïve patients were diagnosed with advanced NSCLC from January 2016 to March 2020 at Hunan Cancer Hospital. After screening, all patients were ≥18 years old and histologically diagnosed of non-squamous NSCLC with stage IV. They were all with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–1. Their driver gene mutations were negative and first line treatments were BC. The characteristics of the patients including sex, age, smoking history, brain metastasis, and status of HER-2, BRAF, KRAS, TP53, M861 mutations are summarized in Table 1.

Treatment

Patients received induction therapy on day 1 of each 21-day period by the regimen of cisplatin (75 mg/m2)/carboplatin (area under the curve, AUC 6), pemetrexed (500 mg/m2), and bevacizumab. Induction therapy was repeated every 3 weeks for a maximum of four cycles. After completion of at least three cycles of induction therapy, patients received maintenance therapy on day 1 of the 21-days cycle comprising pemetrexed (500 mg/m2) and bevacizumab. The dose of bevacizumab in maintenance therapy was the same as induction therapy. Maintenance therapy was repeated every 3 weeks until disease progression or intolerance.

Assessment

Chemotherapy response was evaluated after every two treatment cycles by computed tomography. They were evaluated as complete response (CR), partial response (PR), stable disease (SD), progression disease (PD), or not evaluable according to the Response Evaluation Criteria in Solid Tumor criteria 1.1.9. The ORR was defined as the sum of CR and PR. The disease control rate (DCR) was defined as the sum of CR, PR, and SD. Toxicities were evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The primary endpoint was progression-free survival (PFS). Secondary endpoints were ORR, DCR, and adverse effect.

Statistics Analysis

Descriptive summaries were created for demographic and clinical variables. The Chi-squared test was used to compare subset variables and toxicities. All p values were two-tailed. Kaplan–Meier curves were generated for progression free survival and overall survival. Log-rank tests were used to compare the survival between groups. All statistical analyses were performed using the SPSS 22.0 software for Windows (SPSS Corp., Armonk, NY, United States); p < 0.05 was considered to indicate a statistically significant difference.
RESULTS

Patient Characteristics

Among 1,205 NSCLC patients, 111 patients who received first-line PC combined with bevacizumab were enrolled in this study. Thirty-two patients with EGFR mutations, ALK fusions, or ROS-1 fusions were excluded (Figure 1). A retrospective analysis was performed in 79 NSCLC patients who had received first-line treatment of bevacizumab combined with PC, and 57 of them received bevacizumab at a dose of 7.5 mg/kg and 22 patients received bevacizumab at a dose of 15 mg/kg. The characteristics of the patients, including sex, age, smoking history, brain metastasis, and status of gene mutations, are summarized in Table 1. There were no significant differences in the baseline characteristics. According to the TNM classification for NSCLC patients (AJCC 7th), all patients were diagnosed with stage IV lung adenocarcinoma.

Clinical Efficacy

The treatment responses are listed in Table 2. There was no patient who achieved CR in the whole population. Of the 57 patients in treatment with bevacizumab 7.5 mg/kg group, 26 (45.6%) achieved PR, 23 (40.4%) achieved SD, and 6 (10.5%) achieved PD; and of the 22 patients in the treatment with bevacizumab 15 mg/kg group, 11 (50.0%) achieved PR, 9 (40.9%) achieved SD, and 2 (9.1%) achieved PD. The ORR and DCR in the bevacizumab 7.5 mg/kg group were 45.46 and 86.0%, while in bevacizumab 15 mg/kg group were 50 and 90.9%, respectively. There is no significant difference in the treatment efficacy between patients with different doses of bevacizumab (ORR, \( p = 0.804 \); DCR, \( p = 0.717 \)).

This study met the primary endpoint. The median PFS (mPFS) were 8.0 months (95% CI, 4.8–11.1 months) in the bevacizumab 7.5 mg/kg group and 8.7 months (95% CI, 5.5–11.8 months) in the bevacizumab 15 mg/kg group, respectively (Figure 2). There was no significant difference between the two groups (\( p = 0.766 \)). Moreover, we conducted subgroup analysis according to the clinical variables, and the results showed no significant differences between bevacizumab 7.5 mg/kg group and bevacizumab 15 mg/kg groups (Figure 3).

Toxicity

Most side effects were tolerable (grade 1–2); nine patients (11.4%) had severe adverse events (grade 3–4). As summarized in Table 3, the most common adverse events were leukopenia (26.5%) and liver dysfunction (22.8%) in bevacizumab 7.5 mg/kg group, while leukopenia (40.9%) and proteinuria (22.7%) in bevacizumab 15 mg/kg group. For the grade 3–4 adverse events, the frequencies of hypertension, leukopenia, thrombocytopenia,

---

**TABLE 1 | Characteristics of NSCLC patients.**

| Variables             | Bev 7.5 mg/kg (%) | Bev 15 mg/kg (%) | \( \chi^2 \) | P     |
|----------------------|------------------|-----------------|-------------|-------|
| Total NO. of patients| 57               | 22              |             |       |
| Age                  |                  |                 |             |       |
| Median               | 59.8             | 59.1            | 1.042       | 0.328 |
| Range                | 33–76            | 45–69           |             |       |
| ≥60                  | 29 (50.9)        | 8 (36.4)        |             |       |
| <60                  | 28 (49.1)        | 14 (63.6)       |             |       |
| Sex                  |                  |                 |             |       |
| Male                 | 42 (73.7)        | 15 (68.2)       |             |       |
| Female               | 15 (26.3)        | 7 (31.8)        |             |       |
| Smoking status       |                  |                 |             |       |
| Yes                  | 40 (70.2)        | 13 (59.1)       |             |       |
| No                   | 17 (29.8)        | 9 (40.9)        |             |       |
| Brain metastasis     |                  |                 |             |       |
| Yes                  | 7 (12.3)         | 3 (13.6)        | 0.007       | 0.860 |
| No                   | 50 (87.7)        | 19 (84.4)       |             |       |
| Gene mutation\( ^a \) |                  |                 |             |       |
| Yes                  | 15 (26.3)        | 6 (27.3)        |             |       |
| No                   | 42 (73.7)        | 16 (72.7)       |             |       |

\( ^a \)Gene mutations: HER-2, BRAF, KRAS, TP53, M861 mutations.

\( ^b \)One data grid is expected to be less than 5, which is calculated by the standardized method.

---

**FIGURE 1 | Flow diagram of sample screening.**
vomiting, and liver dysfunction were 3.5, 1.8, 1.8, 1.8, and 1.8% in bevacizumab 7.5 mg/kg group, respectively. The frequencies of grade 3–4 adverse events, including leukopenia, nausea, vomiting, thrombocytopenia, fatigue, and proteinuria, were 9.1, 9.1, 9.1, 4.5, 4.5, and 4.5% in bevacizumab 15 mg/kg group, respectively. The incidence of overall toxicities in 15 mg/kg group is statistically higher than 7.5 mg/kg group (p = 0.001) (Table 4). Meanwhile, the subgroup comparisons of G3-4 adverse events, the rate of leukopenia, and liver dysfunction had been done. However, there was no statistically significant difference of these adverse between two groups. No new safety signals were observed in this study.

DISCUSSION

Bevacizumab has been widely used in anti-tumor therapy in the form of monotherapy and combination therapy. However, there is no standard dosage for bevacizumab. Fatih Kose et al. reported the half-dose bevacizumab experience in relapsed ovarian cancer

TABLE 2 | Summary of treatment response.

| Response | 7.5 mg/kg group (n = 57) (%) | 15 mg/kg group (n = 22) (%) | P value |
|----------|-------------------------------|-----------------------------|---------|
| CR       | —                             | 26 (45.6)                   | —       |
| PR       | 22 (40.4)                     | 11 (50.0)                   | 0.348   |
| SD       | 23 (40.4)                     | 9 (40.9)                    | 0.964   |
| PD       | 6 (10.5)                      | 2 (9.1)                     | 0.188   |
| NE       | 2 (3.5)                       | —                            | —       |
| ORR      | 26 (45.6)                     | 11 (50.0)                   | 0.348   |
| DCR      | 49 (86.0)                     | 20 (90.9)                   | 0.589   |

CR, complete response; DCR, disease control rate; NE, not evaluable; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease.

FIGURE 2 | Plot of Kaplan-Meier estimates of progression-free survival for the bevacizumab 7.5 mg/kg group compared with 15 mg/kg group.

FIGURE 3 | Forest plots of hazard ratios for progression-free survival by subgroups for each bevacizumab group.
patients, following showed the lower dose group has similar effectiveness with lower rate of hypertension (Kose et al., 2020). In NSCLC, serval clinical trials were designed with the selected bevacizumab dose arms or proceeding subgroup analysis. There were few bevacizumab dose comparative studies that have been reported.

The immune checkpoint inhibitors (ICIs) have dramatically changed the landscape of NSCLC treatment. Bevacizumab has been investigated in combination with immunotherapy and chemotherapy. Based on IMPOWER 150 study, combination therapy with atezolizumab, bevacizumab, and chemo [carboplatin + paclitaxel (CP)] has been approved for first-line treatment in advanced non-squamous NSCLC. In exploratory analysis of IMPOWER 150, the arms containing bevacizumab (ABCP and BCP) had lower rate of new brain lesions comparing with ACP arm ACP (ACP 11.9%, n = 48, ABCP 7%, n = 28, BCP 6%, n = 24) (Socinski et al., 2018). On the other hand, the dosage of bevacizumab in this trial (15 mg/kg) should be noticed, because the incidence of AEs leading to bevacizumab withdrawal (13%) was higher than chemo (6%) and atezolizumab (8%) (Dhillon and Syed, 2019). However, we do not have enough immuno-combination therapy cases to proceed with comparative research. In this real-world study, we compared the efficacy and safety of bevacizumab used by 7.5 or 15 mg/kg in stage IV non-squamous NSCLC patients, who were treated by cisplatin/carboplatin, pemetrexed, and bevacizumab. It would offer a reference to improve the effectiveness and safety of immuno-combination therapy which contains bevacizumab.

The results of this study revealed that there was barely noticeable difference of mPFS between 7.5 mg/kg group and 15 mg/kg group. The ORR and DCR were 45.46 and 86.0% in bevacizumab 7.5 mg/kg group and were 50 and 90.9% in bevacizumab 15 mg/kg group, which was consistent with historical research data (Zhou et al., 2014). In AVAPERL (MO22089), patients with advanced NSCLC received first-line bevacizumab 7.5 mg/kg, the mPFS was 7.4 months (Barlesi et al., 2013); while in eCOMPASS (WJOG5610L) and Point Break trial patients received bevacizumab 15 mg/kg, the mPFS was 6.0 months (Zinner et al., 2015; Kreis et al., 2019). AVAIL study shares some similar conclusions with our study. The study compared the treatment results of 7.5 or 15 mg/kg of bevacizumab versus placebo in combination with chemotherapy, and confirmed the superiority of bevacizumab maintenance treatment over placebo. The median PFS of bevacizumab 7.5 mg/kg group and bevacizumab 15 mg/kg group were 6.7 vs. 6.5 months, which was consistent with our data. However, the direct comparison between 7.5 and 15 mg/kg was not performed. In addition, although AVAIL study shows that the overall incidence of serious AEs was higher in the 15 mg/kg bevacizumab plus CG arm (44%) compared with the placebo plus CG and 7.5 mg/kg bevacizumab plus CG arms, the chemotherapy regimens administrated in AVAIL study is gemcitabine, while the current superior regimen for the treatment of lung adenocarcinoma is pemetrexed (Huang et al., 2012; Shi et al., 2013; Hu et al., 2016). It is worth noting that most of historical clinical trials mentioned above did not compare the efficacy and safety of the two doses of bevacizumab directly. In our study, the overall incidence of AEs was higher in the high-dose group. Since the majority of AEs reported during this study were leukopenia, liver dysfunction, and proteinuria, we compared the rate of these selected AEs in two groups. The incidence of liver dysfunction was higher in the 7.5 mg/kg group and may result from the small sample size of 15 mg/kg group. Moreover, the incidence of proteinuria which mainly arising from bevacizumab was much higher in the 15 mg/kg group.

### Table 3: Treatment related adverse events

| Adverse events         | Bev 7.5 mg/kg (n = 57) | Bev 15 mg/kg (n = 22) |
|------------------------|------------------------|-----------------------|
|                        | Grade 1–2 n (%)        | Grade 3–4 n (%)       | Total n (%)          | Grade 1–2 n (%) | Grade 3–4 n (%) | Total n (%) |
| Leukopenia             | 14 (24.6)              | 1 (1.8)               | 15 (26.3)            | 7 (31.8)        | 2 (9.1)         | 9 (40.9)     |
| Anemia                 | 1 (1.8)                | 0                     | 1 (1.8)              | 1 (4.5)         | 0               | 1 (4.5)      |
| Thrombocytopenia       | 1 (1.8)                | 1 (1.8)               | 2 (3.5)              | 0               | 1 (4.5)         | 1 (4.5)      |
| Nausea                 | 1 (1.8)                | 0                     | 1 (1.8)              | 0               | 2 (9.1)         | 2 (9.1)      |
| Fatigue                | 0                      | 0                     | 0                    | 0               | 2 (9.1)         | 2 (9.1)      |
| Vomiting               | 2 (3.5)                | 1 (1.8)               | 3 (5.3)              | 0               | 2 (9.1)         | 2 (9.1)      |
| Liver dysfunction      | 12 (21.0)              | 1 (1.8)               | 13 (22.8)            | 3 (13.6)        | 0               | 3 (13.6)     |
| Hemoptysis             | 2 (3.5)                | 0                     | 2 (3.5)              | 3 (13.6)        | 0               | 3 (13.6)     |
| Hypertension           | 0                      | 2 (3.5)               | 2 (3.5)              | 0               | 0               | 0            |
| Proteinuria            | 4 (7.0)                | 0                     | 4 (7.0)              | 4 (18.2)        | 1 (4.5)         | 5 (22.7)     |
| Abdominal pain         | 1 (1.8)                | 0                     | 1 (1.8)              | 0               | 0               | 0            |
| Renal dysfunction      | 3 (5.3)                | 0                     | 3 (5.3)              | 0               | 0               | 0            |
| Edema                  | 1 (1.8)                | 0                     | 1 (1.8)              | 0               | 0               | 0            |

### Table 4: Comparison of adverse events

| Adverse events       | Bev 7.5 mg/kg | Bev 15 mg/kg | P value |
|----------------------|--------------|--------------|---------|
|                      | N (%)        | N (%)        |         |
| Total                | 21 (36.8)    | 17 (77.3)    | 0.001   |
| Grade 3–4            | 4 (7.0)      | 5 (22.7)     | 0.106*  |
| Leukopenia           | 15 (26.3)    | 9 (40.9)     | 0.465*  |
| Liver dysfunction    | 13 (22.8)    | 3 (13.6)     | 0.751*  |
| Proteinuria          | 4 (7.0)      | 5 (22.7)     | 0.106*  |

*Fisher’s Exact Test was applied.*

In addition to the reported AEs, the incidence of Grade 3–4 liver dysfunction was 2 (9.1%) in the 15 mg/kg group. The incidence of Grade 3–4 proteinuria was 1 (4.5%) in the 15 mg/kg group.

The incidence of Grade 3–4 hypertension was significantly higher in the 15 mg/kg group compared to the 7.5 mg/kg group (13.6% vs. 3.5%, P = 0.001).

The incidence of Grade 3–4 vomiting was 2 (9.1%) in the 15 mg/kg group.

The incidence of Grade 3–4 leukopenia was 9 (40.9%) in the 15 mg/kg group.

The incidence of Grade 3–4 liver dysfunction was 3 (13.6%) in the 15 mg/kg group.

The incidence of Grade 3–4 proteinuria was 1 (4.5%) in the 15 mg/kg group.

The incidence of Grade 3–4 edema was 1 (4.5%) in the 15 mg/kg group.

The incidence of Grade 3–4 abdominal pain was 0 in both groups.

The incidence of Grade 3–4 renal dysfunction was 0 in both groups.

The incidence of Grade 3–4 anemia was 1 (4.5%) in the 15 mg/kg group.

The incidence of Grade 3–4 leukopenia was 1 (4.5%) in the 15 mg/kg group.

The incidence of Grade 3–4 liver dysfunction was 1 (4.5%) in the 15 mg/kg group.

The incidence of Grade 3–4 proteinuria was 1 (4.5%) in the 15 mg/kg group.

The incidence of Grade 3–4 edema was 1 (4.5%) in the 15 mg/kg group.

The incidence of Grade 3–4 abdominal pain was 0 in both groups.

The incidence of Grade 3–4 renal dysfunction was 0 in both groups.

The incidence of Grade 3–4 anemia was 1 (4.5%) in the 15 mg/kg group.

The incidence of Grade 3–4 leukopenia was 1 (4.5%) in the 15 mg/kg group.

The incidence of Grade 3–4 liver dysfunction was 1 (4.5%) in the 15 mg/kg group.

The incidence of Grade 3–4 proteinuria was 1 (4.5%) in the 15 mg/kg group.

The incidence of Grade 3–4 edema was 1 (4.5%) in the 15 mg/kg group.
The baseline characteristics are mostly identical in both groups, but for the age of ≥60 years old, the percentage in high dose group was much lower, and we did propensity score matching (PSM 1:2 match on the nearest neighbor) to balance the covariate. Matched sets of low-dose group patients (n = 44) and high dose group patients (n = 22) who share a similar value of the propensity score of age was analyzed. We did not find any significant difference (p = 0.864); the result is consistent with that in overall sample.

There are some limitations in this study. Firstly, the sample size is small and may increases the likelihood of a Type II error, which decreases the power of the study. Secondly, several patients crossed over from high dose group to low dose group in maintenance therapy, and that may affect the results of side-effects analysis. It is necessary to research whether the dose of maintenance therapy is consistent with that of induction therapy. Lastly, we conducted subgroup analyses of PFS in the two groups according to the clinical variables, but no significant differences were observed in all the subgroups. It might be because the sample size was too small, and a larger sample size is needed in further investigations.

In conclusion, chemotherapy combined with bevacizumab 7.5 and 15 mg/kg reach the similar PFS, ORR, and DCR in advanced non-driver gene mutation NSCLC patients. No significant difference of efficacy was observed between the two groups. However, the incidences of overall toxicities were higher in the 15 mg/kg group. Meanwhile, the medical fees of half-dose bevacizumab administration were significantly lower than that of 15 mg/kg; as a result, considering the cost-effectiveness, the 7.5 mg/kg administration was logically preferred.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, and further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics Committee of Hunan cancer hospital. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

Study design was contributed by C-HZ, FY, W-JJ, ZW, and NY. C-HZ and FY took the lead in data collection and data analysis, assisted by W-JJ, Y-CZ, H-YY, LZ, LL, YX, and F-XZ. Data interpretation was performed by C-HZ, with assistance from the other authors. The manuscript was written primarily by C-HZ, FY, and W-JJ, and revised by ZW and NY. All authors contributed to the article and approved the submitted version.

FUNDING

This Project were supported by the Hunan Provincial Natural Science Foundation of China (Grant No. 2020JJ9044) and Changsha Municipal Natural Science Foundation (Grant No. kq2014208).

REFERENCES

Barlesi, F., Scherpereel, A., Rittmeyer, A., Pazzola, A., Ferrer Tur, N., Kim, J. H., et al. (2013). Randomized Phase III Trial of Maintenance Bevacizumab with or without Pemetrexed after First-Line Induction with Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonquamous Non-small-cell Lung Cancer: AVAPERL (MO20899). J. Clin. Oncol. 31, 3004–3011. doi:10.1200/JCO.2012.42.3749

Chen, W., Zheng, R., Baade, P. D., Zhang, S., Zeng, H., Bray, F., et al. (2016). Cancer Statistics in China, 2015. CA Cancer J. Clin. 66, 115–132. doi:10.3322/cac.231538

Crino, L., Dansin, E., Garrido, P., Griesinger, F., Laskin, J., Pavlakis, N., et al. (2010). Safety and Efficacy of First-Line Bevacizumab-Based Therapy in Advanced Non-squamous Non-small-cell Lung Cancer (SAiL, MO19390): a Phase 4 Study. Lancet Oncol. 11, 733–740. doi:10.1016/S1470-2045(10)70151-0

Dhillon, S., and Syed, Y. Y. (2019). Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonquamous NSCLC. Target. Oncol. 14, 759–768. doi:10.1007/s11523-019-00686-w

Hanna, N. H., Schneider, B. J., Temin, S., Baker, S., Jr., Brabمهر, J., Ellis, P. M., et al. (2020). Therapy for Stage IV Non-small-cell Lung Cancer without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. J. Clin. Oncol. 38, 1608–1632. doi:10.1200/JCO.20.03022

Hu, X., Pu, K., Feng, X., Wen, S., Fu, X., Guo, C., et al. (2016). Role of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One 11, e0149247. doi:10.1371/journal.pone.0149247

Huang, Y., Liu, Y., Zhou, J., Xu, N., Li, B., Wu, G., et al. (2012). A Randomized, Controlled, Multicenter Clinical Trial Comparing Pemetrexed/cisplatin and Gemcitabine/cisplatin as First-Line Treatment for Advanced Nonquamous Non-small Cell Lung Cancer. Zhongguo Fei Ai Za Zhi 15, 576–582. doi:10.3779/jissn.1009-3419.2012.10.003

Kose, F., Alemdaroglu, S., Mertsoylu, H., Besen, A. A., Guler, O. C., Simsek, S. Y., et al. (2020). Half-dose Bevacizumab Experience in Relapsed Ovarian Cancer Patients in Turkey Due to Formal Regulations: Similar Effectiveness with Lower Rate of Hypertension. J. BUON 25, 1928–1934.

Kreis, N. N., Louwen, F., and Yuan, J. (2019). The Multifaceted P21 (Cip1/Waf1/CDKN1A) Inhibitor of Yes-Associated Protein 1 in Triple-Negative Breast Cancer: A Phase II Trial in Unresectable Triple-Negative Breast Cancer. Cancer Sci. 110, 561–567. doi:10.1111/cas.13888

Miller, K. D., Nogueira, L., Mariotto, A. B., Rowland, J. H., Yabroff, K. R., Alfano, C. M., et al. (2019). Cancer Treatment and Survivorship Statistics, 2019. CA Cancer J. Clin. 69, 363–385. doi:10.3322/caac.21565

Patel, J. D., Socinski, M. A., Garon, E. B., Reynolds, C. H., Spigel, D. R., Olsen, M. R., et al. (2013). PointBreak: a Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab versus Pemetrexed Plus Carboplatin Followed by Maintenance Bevacizumab in Patients with Stage IIIIB or IV Nonquamous Non-small cell Lung Cancer. J. Clin. Oncol. 31, 4349–4357. doi:10.1200/JCO.2012.47.9626

Reck, M., Rodriguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., et al. (2019). Updated Analysis of KEYNOTE-024: Pembrolizumab versus Platinum-Based Chemotherapy for Advanced Non-small-cell Lung Cancer with PD-L1 Tumor Proportion Score of 50% or Greater. J. Clin. Oncol. 37, 537–546. doi:10.1200/JCO.18.00149
Reck, M., Von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., et al. (2009). Phase III Trial of Cisplatin Plus Gemcitabine with Either Placebo or Bevacizumab as First-Line Therapy for Nonsquamous Non-small-cell Lung Cancer: AVAiL. J. Clin. Oncol. 27, 1227–1234. doi:10.1200/JCO.2007.14.5466

Rocco, D., Della Gravara, L., Battiloro, C., and Gridelli, C. (2019). The Role of Combination Chemo-Immunotherapy in Advanced Non-small Cell Lung Cancer. Expert Rev. Anticancer Ther. 19, 561–568. doi:10.1080/14737140.2019.1631800

Scagliotti, G. V., Parikh, P., Von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., et al. (2008). Phase III Study Comparing Cisplatin Plus Gemcitabine with Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients with Advanced-Stage Non-small-cell Lung Cancer. J. Clin. Oncol. 26, 3543–3551. doi:10.1200/JCO.2007.15.0375

Shan, F., Zhang, B., Sun, L., Xie, L., Shen, M., and Ruan, S. (2018). The Role of Combination Maintenance with Pemetrexed and Bevacizumab for Advanced Stage Nonsquamous Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Biomed. Res. Int. 2018, 5839081. doi:10.1155/2018/5839081

Shi, X., Yu, X. M., Zhang, Y. P., and Zhao, J. (2013). Efficacy and Safety of Pemetrexed or Gemcitabine Combined with Carboplatin as the First-Line Therapy in Elderly Patients with Advanced Non-small Cell Lung Cancer. Zhonghua Zhong Liu Za Zhi 35, 221–224. doi:10.3760/cma.j.issn.0253-3766.2013.03.013

Siegel, R. L., Miller, K. D., and Jemal, A. (2018). Cancer Statistics, 2018. CA Cancer J. Clin. 68, 7–30. doi:10.3322/caac.21442

Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., et al. (2018). Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N. Engl. J. Med. 378, 2288–2301. doi:10.1056/NEJMo1716948

Tsutani, Y., Miyata, Y., Masuda, T., Fujitaka, K., Doi, M., Aways, Y., et al. (2018). Multicenter Phase II Study on Cisplatin, Pemetrexed, and Bevacizumab Followed by Maintenance with Pemetrexed and Bevacizumab for Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer: MAP Study. BMC Cancer 18, 1231. doi:10.1186/s12885-018-5146-3

Xu, J. H., Hu, S. L., Shen, G. D., and Shen, G. (2016). Tumor Suppressor Genes and Their Underlying Interactions in Paclitaxel Resistance in Cancer Therapy. Cancer Cell Int 16, 13. doi:10.1186/s12935-016-0290-9

Zhou, C., Wu, Y. L., Chen, G., Liu, X., Zhu, Y., Lu, S., et al. (2015). BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients with Advanced or Recurrent Nonsquamous Non-small-cell Lung Cancer. J. Clin. Oncol. 33, 2197–2204. doi:10.1200/JCO.2014.59.4424

Zhou, C. C., Bai, C. X., Guan, Z. Z., Jiang, G. L., Shi, Y. K., Wang, M. Z., et al. (2014). Safety and Efficacy of First-Line Bevacizumab Combination Therapy in Chinese Population with Advanced Non-squamous NSCLC: Data of Subgroup Analyses from MO19390 (SAI) Study. Clin. Transl Oncol. 16, 463–468. doi:10.1007/s12094-013-1102-5

Zeuner, R. G., Obasaju, C. K., Spigel, D. R., Weaver, R. W., Beck, J. T., Waterhouse, D. M., et al. (2015). PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients Ith Advanced Nonsquamous Non-small-cell Lung Cancer. J. Thorac. Oncol. 10, 134–142. doi:10.1097/JTO.0000000000000366

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Zhou, Yang, Jiang, Zhang, Yang, Zeng, Liu, Xiong, Zeng, Wang and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.